These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6507124)

  • 1. Mental impairment in Parkinson's disease. The role of anticholinergic drugs.
    Meco G; Casacchia M; Lazzari R; Franzese A; Castellana F; Carta A; Iannuccelli M; Agnoli A
    Acta Psychiatr Belg; 1984; 84(4):325-35. PubMed ID: 6507124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dementia and treatment with L-dopa in Parkinson's disease.
    Hietanen M; Teräväinen H
    Mov Disord; 1988; 3(3):263-70. PubMed ID: 3193964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease.
    Hauser RA; Olanow CW
    Mov Disord; 1993 Oct; 8(4):512-4. PubMed ID: 8232363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A psychometric study of a group of Parkinsonian patients].
    Gil R; Lefevre JP
    Rev Neurol (Paris); 1980; 135(12):903-22. PubMed ID: 7466117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Parkinson's disease with orphenadrine alone and in combination with L-dopa.
    Bassi S; Albizzati MG; Calloni E; Sbacchi M; Frattola L
    Br J Clin Pract; 1986 Jul; 40(7):273-5. PubMed ID: 3741741
    [No Abstract]   [Full Text] [Related]  

  • 6. [Combined treatment of parkinsonism with L-dopa and Parkopan].
    Lukasiewicz K
    Wiad Lek; 1977 May; 30(10):775-7. PubMed ID: 867994
    [No Abstract]   [Full Text] [Related]  

  • 7. Confusion, dementia and anticholinergics in Parkinson's disease.
    de Smet Y; Ruberg M; Serdaru M; Dubois B; Lhermitte F; Agid Y
    J Neurol Neurosurg Psychiatry; 1982 Dec; 45(12):1161-4. PubMed ID: 7161613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic dementia in Parkinson disease treated by long-term administration of anticholinergic drug--evaluation of neuropsychological test, PET, and SPECT].
    Nishiyama K; Mizuno T; Sakuta M; Kurisaki H; Momose T
    Rinsho Shinkeigaku; 1991 Jun; 31(6):625-31. PubMed ID: 1934777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Parkinson's disease and mental deterioration. Apropos of 30 cases].
    Mouren P; Poinso Y; Oppenheim G; Mouren A; Nguyen Quang N
    Ann Med Psychol (Paris); 1983 Nov; 141(9):945-56. PubMed ID: 6666920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anticholinergics and levodopa in Parkinson's disease: an unnecessary combination in patients treated for the 1st time].
    Giménez-Roldán S; Mateo D; Gil Núñez A
    Rev Clin Esp; 1980 Dec; 159(6):403-7. PubMed ID: 7221107
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
    Reddy S; Factor SA; Molho ES; Feustel PJ
    Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Modification of disturbed visual-spatial performance in patients with Parkinson's disease by treatment with L-dopa].
    Jacobi P; Schneider E; Gundelsheimer W; Fischer PA
    Nervenarzt; 1974 Nov; 45(11):588-94. PubMed ID: 4453348
    [No Abstract]   [Full Text] [Related]  

  • 14. Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination.
    Nishiyama K; Mizuno T; Sakuta M; Kurisaki H
    Adv Neurol; 1993; 60():479-83. PubMed ID: 8420174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intellectual deterioration in Parkinson patients treated with L-dopa. Long-term prognostic factors].
    Bonduelle M; Degos CF
    Int J Neurol; 1979; 13(1-4):255-61. PubMed ID: 263185
    [No Abstract]   [Full Text] [Related]  

  • 20. [Combined treatment of Parkinsonism with levopa, midantan and anticholinergic drugs].
    Evtushenko SK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1976 Dec; 76(12):1797-1802. PubMed ID: 1015115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.